New drug DD01 shows promise for fatty liver in early trial
Disease control
Completed
This Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will s…
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC